An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics, Inc. (GLYC) announced a conference call on August 3, 2022, at 8:30 a.m. ET, to discuss its second quarter financial results. Investors can participate via a registration link provided in the announcement or access a live webcast through the company’s website. GlycoMimetics is focused on developing glycobiology-based therapies for cancers like acute myeloid leukemia and inflammatory diseases. The company aims to advance its drug candidates to address significant healthcare needs.
Positive
The company is advancing a pipeline of wholly owned drug candidates.
Focus on high unmet needs in cancer and inflammatory diseases.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter financial results on Wednesday, August 3, 2022, at 8:30 a.m. ET.
To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
A live webcast of the call will be available on the “Investors” tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
When will GlycoMimetics hold its second quarter financial results call?
GlycoMimetics will hold its second quarter financial results call on August 3, 2022, at 8:30 a.m. ET.
How can I access the GlycoMimetics conference call?
You can access the GlycoMimetics conference call by registering through the provided registration link, or by joining the live webcast on their website.
What is GlycoMimetics focusing on in its drug development?
GlycoMimetics is focused on discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia, and inflammatory diseases.
